Compare · BSX vs SSKN
BSX vs SSKN
Side-by-side comparison of Boston Scientific Corporation (BSX) and Strata Skin Sciences Inc. (SSKN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and SSKN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.26B, about 1475.9x SSKN ($49.0M).
- Over the past year, BSX is down 53.1% and SSKN is down 88.5% - BSX leads by 35.3 points.
- BSX has hit the wire 10 times in the past 4 weeks while SSKN has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 0 for SSKN).
- Company
- Boston Scientific Corporation
- Strata Skin Sciences Inc.
- Price
- -
- -
- Market cap
- $72.26B
- $49.0M
- 1M return
- +9.58%
- +0.00%
- 1Y return
- -53.13%
- -88.47%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2005
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Strata Skin Sciences Inc.
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC excimer laser and VTRAC lamp systems that are used for the treatment of psoriasis, vitiligo, atopic dermatitis, eczema, and other skin disorders. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Latest BSX
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
- SEC Form 10-Q filed by Boston Scientific Corporation
Latest SSKN
- STRATA Skin Sciences Appoints Medical Device Commercial Leader Erica Jordan as Chief Executive Officer
- New Peer-Reviewed Publication Confirms Unprecedented Response Rates for STRATA's Excimer Laser Combined with JAK Inhibitors in Pediatric Vitiligo
- SEC Form 10-K filed by Strata Skin Sciences Inc.
- SEC Form EFFECT filed by Strata Skin Sciences Inc.
- SEC Form EFFECT filed by Strata Skin Sciences Inc.
- SEC Form EFFECT filed by Strata Skin Sciences Inc.
- SEC Form 15-12G filed by Strata Skin Sciences Inc.
- SEC Form POS AM filed by Strata Skin Sciences Inc.
- SEC Form POS AM filed by Strata Skin Sciences Inc.
- SEC Form S-8 POS filed by Strata Skin Sciences Inc.